High blood pressure is one of the world’s most common health problems, and it often causes damage without producing obvious warning signs.
A new animal study suggests that controlling inflammation in a more targeted way may one day help lower blood pressure while also repairing some of the damage it causes.
High blood pressure, also called hypertension, happens when blood pushes against artery walls with too much force for long periods.
This forces the heart to work harder and can gradually damage blood vessels, kidneys, the brain and other organs.
Doctors already have many effective medicines for lowering blood pressure.
These drugs work in different ways, such as helping the body remove extra salt and water, relaxing blood vessels or blocking hormones and nerve signals that raise blood pressure.
Scientists know that two body systems are especially important in hypertension. One involves the nerves that prepare the body for action, while another uses hormones to control blood pressure, salt and fluid levels.
Researchers are now paying more attention to another possible contributor: long-lasting inflammation. Inflammation is normally part of the body’s defense and repair system, but when it continues for too long it can damage healthy tissue.
A recent study examined whether a drug called Compound17b, or Cmpd17b, could influence this process. Rather than broadly shutting down the immune system, the experimental drug acts on switches found on several types of cells that help control inflammation and healing.
These switches, known as formyl peptide receptors, are found on immune cells as well as cells in the heart and kidneys. Scientists are interested in them because they may help the body move from an inflammatory state toward healing.
The researchers tested Cmpd17b in male mice with a form of high blood pressure largely driven by overactive nerve signals. They also treated mice with normal blood pressure so they could see whether the drug lowered pressure when it was not needed.
A total of 45 mice were included in the experiment, and treatment lasted for 28 days. The researchers continuously monitored blood pressure, heart rate and physical activity.
The experimental drug lowered average arterial blood pressure by about 6 millimeters of mercury in mice with hypertension. Importantly, it did not lower blood pressure in mice whose pressure was already normal.
The effect also developed gradually rather than causing a sudden fall in blood pressure. The largest reduction occurred during the part of the day when the mice were most active and their blood pressure naturally reached its highest levels.
But lowering blood pressure was only one part of the study. The researchers also wanted to know whether the treatment could repair damage that hypertension had already caused.
Long-term high blood pressure can cause fibrosis, which is the buildup of stiff scar-like tissue inside organs and blood vessels. This can make tissues less flexible and interfere with normal function.
Cmpd17b reduced scarring in the kidneys of hypertensive mice. The researchers also found reductions in collagen buildup in the aorta, the body’s largest artery, and in the left ventricle, the heart’s main pumping chamber.
The kidneys appeared to show particularly strong signs of tissue repair. This is important because high blood pressure and kidney disease can worsen each other in a damaging cycle.
The researchers also found major changes in the aorta. Treatment made the artery about 37% more flexible and reduced the thickness of its wall by about 22%.
Healthy arteries need to stretch as the heart pumps blood through them. When arteries become thick and stiff, the heart has to work harder and blood pressure can become more difficult to control.
However, the drug did not fix every problem caused by hypertension. It did not clearly improve the heart’s pumping performance, and it did not fully restore normal function in smaller blood vessels.
This mixed result is important when judging the study. Cmpd17b appears promising because it affected both blood pressure and some forms of tissue damage, but it was not a complete treatment for all the effects of hypertension.
The study also involved mice rather than people. Animal models can help scientists understand how a treatment works, but many drugs that perform well in mice do not eventually prove safe or effective in humans.
Another limitation is that the experiment involved only 45 male mice and lasted four weeks. Human hypertension often continues for decades and occurs in people with very different ages, health conditions and causes of high blood pressure.
The findings therefore should not change how patients currently manage hypertension. Existing blood pressure medicines and healthy lifestyle changes remain the proven ways to reduce the risk of heart attack, stroke, kidney disease and other complications.
What makes the research interesting is its different approach to inflammation. Instead of simply suppressing immune activity, the researchers are exploring whether the body’s own healing process can be encouraged to resolve harmful inflammation and repair damaged tissue.
If future research confirms the findings, drugs acting on these inflammation-related pathways might eventually complement existing blood pressure treatments. Larger animal studies would be needed first, followed by carefully controlled human trials.
The research was published in the journal Communications Biology in 2026. It provides early evidence that targeting the way inflammation is resolved may help lower high blood pressure while reducing some of the scarring it leaves behind.
Overall, the 6 mmHg reduction in average pressure and improvements in kidney and artery damage are encouraging, especially because normal mice did not experience unnecessary blood pressure lowering.
Still, this is early laboratory research, and the small animal study cannot tell us whether the same benefits will occur safely in people.
